Global and Regional Overactive Bladder Treatment Market

Overactive Bladder Treatment Comprehensive Study by Type (Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training), Therapies (Biofeedback, Kegel Exercise), Medications (Bladder Relaxant), Specialists (Primary Care Provider, Geriatrician, Physiotherapist, Urologist, Obgyn Doctor)), Application (Men, Women, Children), Surgery Type (Sacral Nerve Stimulation, Urinary Diversion, Cystoplasty, Bladder Removal), Diagnosis Types (Urine Sample, Physical Examination, Bladder Scan, Urodynamic Testing, Cystoscopy) Players and Region - Global Market Outlook to 2026

Overactive Bladder Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Overactive bladder causes change or problems in urine to create overactive bladder diseases. There is strong growth potential in the United State region, where 33 million Americans affected by an overactive bladder. It could be a medical composite. Due to the increasing ration of this disease makes companies invest in this market, with advanced technologies.This growth is primarily driven by Increasing Number of Patients with Over-75-Year-Old and Increasing Number of Therapies and Increasing Research and Development Investment.

Globally, a noticeable market trend is evident Increasing Concentration on Physical Examination of Disease by Focusing On Your Abdomen and Genitals . Major Players, such as Allergan PLC (Ireland), Astellas Pharma Inc. (Japan), Cogentix Medical Inc. (United States), Endo International PLC (Ireland), Hisamitsu Pharmaceutical Co. Inc. (Japan), Medtronic PLC (Medtronic PLC), Pfizer Inc. (Pfizer Inc.), Sanofi (France), Teva Pharmaceutical Industries Limited (Israel) and Mayo Clinic (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In Apr 2019, Zydus Cadila announced to received tentative approval from the United States Food and Drug Administration to market tablets for generic Mirabegron extended-release tablets in the strengths of 25 mg and 50 mg. These products used in the treatment of overactive bladder

Market Drivers
  • Increasing Number of Patients with Over-75-Year-Old
  • Increasing Number of Therapies and Increasing Research and Development Investment

Market Trend
  • Increasing Concentration on Physical Examination of Disease by Focusing On Your Abdomen and Genitals
  • Urinary Incontinence
  • Increasing Consumer Concern towards Natural Therapies

Restraints
  • After The Treatment of Overactive Bladder, Patient Can Suffer From Various Infection, Other Health Issues, Which Can Hamper the Growth of Market

Opportunities
Strong Opportunity For Overactive Bladder Patients By Increasing Number Treatments Based On Therapy

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Overactive Bladder Treatment Study Sheds Light on
— The Overactive Bladder Treatment Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Overactive Bladder Treatment industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Overactive Bladder Treatment industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training)
  • Therapies (Biofeedback, Kegel Exercise)
  • Medications (Bladder Relaxant)
  • Specialists (Primary Care Provider, Geriatrician, Physiotherapist, Urologist, Obgyn Doctor)
By Application
  • Men
  • Women
  • Children
By Surgery Type
  • Sacral Nerve Stimulation
  • Urinary Diversion
  • Cystoplasty
  • Bladder Removal

By Diagnosis Types
  • Urine Sample
  • Physical Examination
  • Bladder Scan
  • Urodynamic Testing
  • Cystoscopy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Patients with Over-75-Year-Old
      • 3.2.2. Increasing Number of Therapies and Increasing Research and Development Investment
    • 3.3. Market Trends
      • 3.3.1. Increasing Concentration on Physical Examination of Disease by Focusing On Your Abdomen and Genitals
      • 3.3.2. Urinary Incontinence
      • 3.3.3. Increasing Consumer Concern towards Natural Therapies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Overactive Bladder Treatment, by Type, Application, Surgery Type, Diagnosis Types and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Overactive Bladder Treatment (Value)
      • 5.2.1. Global Overactive Bladder Treatment by: Type (Value)
        • 5.2.1.1. Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training)
        • 5.2.1.2. Therapies (Biofeedback, Kegel Exercise)
        • 5.2.1.3. Medications (Bladder Relaxant)
        • 5.2.1.4. Specialists (Primary Care Provider, Geriatrician, Physiotherapist, Urologist, Obgyn Doctor)
      • 5.2.2. Global Overactive Bladder Treatment by: Application (Value)
        • 5.2.2.1. Men
        • 5.2.2.2. Women
        • 5.2.2.3. Children
      • 5.2.3. Global Overactive Bladder Treatment by: Surgery Type (Value)
        • 5.2.3.1. Sacral Nerve Stimulation
        • 5.2.3.2. Urinary Diversion
        • 5.2.3.3. Cystoplasty
        • 5.2.3.4. Bladder Removal
      • 5.2.4. Global Overactive Bladder Treatment by: Diagnosis Types (Value)
        • 5.2.4.1. Urine Sample
        • 5.2.4.2. Physical Examination
        • 5.2.4.3. Bladder Scan
        • 5.2.4.4. Urodynamic Testing
        • 5.2.4.5. Cystoscopy
      • 5.2.5. Global Overactive Bladder Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Overactive Bladder Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan PLC (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Astellas Pharma Inc. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cogentix Medical Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Endo International PLC (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Hisamitsu Pharmaceutical Co. Inc. (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Medtronic PLC (Medtronic PLC)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (Pfizer Inc.)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceutical Industries Limited (Israel)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mayo Clinic (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Overactive Bladder Treatment Sale, by Type, Application, Surgery Type, Diagnosis Types and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Overactive Bladder Treatment (Value)
      • 7.2.1. Global Overactive Bladder Treatment by: Type (Value)
        • 7.2.1.1. Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training)
        • 7.2.1.2. Therapies (Biofeedback, Kegel Exercise)
        • 7.2.1.3. Medications (Bladder Relaxant)
        • 7.2.1.4. Specialists (Primary Care Provider, Geriatrician, Physiotherapist, Urologist, Obgyn Doctor)
      • 7.2.2. Global Overactive Bladder Treatment by: Application (Value)
        • 7.2.2.1. Men
        • 7.2.2.2. Women
        • 7.2.2.3. Children
      • 7.2.3. Global Overactive Bladder Treatment by: Surgery Type (Value)
        • 7.2.3.1. Sacral Nerve Stimulation
        • 7.2.3.2. Urinary Diversion
        • 7.2.3.3. Cystoplasty
        • 7.2.3.4. Bladder Removal
      • 7.2.4. Global Overactive Bladder Treatment by: Diagnosis Types (Value)
        • 7.2.4.1. Urine Sample
        • 7.2.4.2. Physical Examination
        • 7.2.4.3. Bladder Scan
        • 7.2.4.4. Urodynamic Testing
        • 7.2.4.5. Cystoscopy
      • 7.2.5. Global Overactive Bladder Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Overactive Bladder Treatment: by Type(USD Million)
  • Table 2. Overactive Bladder Treatment Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training) , by Region USD Million (2015-2020)
  • Table 3. Overactive Bladder Treatment Therapies (Biofeedback, Kegel Exercise) , by Region USD Million (2015-2020)
  • Table 4. Overactive Bladder Treatment Medications (Bladder Relaxant) , by Region USD Million (2015-2020)
  • Table 5. Overactive Bladder Treatment Specialists (Primary Care Provider, Geriatrician, Physiotherapist, Urologist, Obgyn Doctor) , by Region USD Million (2015-2020)
  • Table 6. Overactive Bladder Treatment: by Application(USD Million)
  • Table 7. Overactive Bladder Treatment Men , by Region USD Million (2015-2020)
  • Table 8. Overactive Bladder Treatment Women , by Region USD Million (2015-2020)
  • Table 9. Overactive Bladder Treatment Children , by Region USD Million (2015-2020)
  • Table 10. Overactive Bladder Treatment: by Surgery Type(USD Million)
  • Table 11. Overactive Bladder Treatment Sacral Nerve Stimulation , by Region USD Million (2015-2020)
  • Table 12. Overactive Bladder Treatment Urinary Diversion , by Region USD Million (2015-2020)
  • Table 13. Overactive Bladder Treatment Cystoplasty , by Region USD Million (2015-2020)
  • Table 14. Overactive Bladder Treatment Bladder Removal , by Region USD Million (2015-2020)
  • Table 15. Overactive Bladder Treatment: by Diagnosis Types(USD Million)
  • Table 16. Overactive Bladder Treatment Urine Sample , by Region USD Million (2015-2020)
  • Table 17. Overactive Bladder Treatment Physical Examination , by Region USD Million (2015-2020)
  • Table 18. Overactive Bladder Treatment Bladder Scan , by Region USD Million (2015-2020)
  • Table 19. Overactive Bladder Treatment Urodynamic Testing , by Region USD Million (2015-2020)
  • Table 20. Overactive Bladder Treatment Cystoscopy , by Region USD Million (2015-2020)
  • Table 21. South America Overactive Bladder Treatment, by Country USD Million (2015-2020)
  • Table 22. South America Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 23. South America Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 24. South America Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 25. South America Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 26. Brazil Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 27. Brazil Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 28. Brazil Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 29. Brazil Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 30. Argentina Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 31. Argentina Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 32. Argentina Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 33. Argentina Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 34. Rest of South America Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 35. Rest of South America Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 36. Rest of South America Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 37. Rest of South America Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 38. Asia Pacific Overactive Bladder Treatment, by Country USD Million (2015-2020)
  • Table 39. Asia Pacific Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 40. Asia Pacific Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 41. Asia Pacific Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 42. Asia Pacific Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 43. China Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 44. China Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 45. China Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 46. China Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 47. Japan Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 48. Japan Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 49. Japan Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 50. Japan Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 51. India Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 52. India Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 53. India Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 54. India Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 55. South Korea Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 56. South Korea Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 57. South Korea Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 58. South Korea Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 59. Taiwan Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 60. Taiwan Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 61. Taiwan Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 62. Taiwan Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 63. Australia Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 64. Australia Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 65. Australia Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 66. Australia Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 71. Europe Overactive Bladder Treatment, by Country USD Million (2015-2020)
  • Table 72. Europe Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 73. Europe Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 74. Europe Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 75. Europe Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 76. Germany Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 77. Germany Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 78. Germany Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 79. Germany Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 80. France Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 81. France Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 82. France Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 83. France Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 84. Italy Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 85. Italy Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 86. Italy Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 87. Italy Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 88. United Kingdom Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 89. United Kingdom Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 90. United Kingdom Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 91. United Kingdom Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 92. Netherlands Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 93. Netherlands Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 94. Netherlands Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 95. Netherlands Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 96. Rest of Europe Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 97. Rest of Europe Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 98. Rest of Europe Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 99. Rest of Europe Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 100. MEA Overactive Bladder Treatment, by Country USD Million (2015-2020)
  • Table 101. MEA Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 102. MEA Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 103. MEA Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 104. MEA Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 105. Middle East Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 106. Middle East Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 107. Middle East Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 108. Middle East Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 109. Africa Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 110. Africa Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 111. Africa Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 112. Africa Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 113. North America Overactive Bladder Treatment, by Country USD Million (2015-2020)
  • Table 114. North America Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 115. North America Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 116. North America Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 117. North America Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 118. United States Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 119. United States Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 120. United States Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 121. United States Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 122. Canada Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 123. Canada Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 124. Canada Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 125. Canada Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 126. Mexico Overactive Bladder Treatment, by Type USD Million (2015-2020)
  • Table 127. Mexico Overactive Bladder Treatment, by Application USD Million (2015-2020)
  • Table 128. Mexico Overactive Bladder Treatment, by Surgery Type USD Million (2015-2020)
  • Table 129. Mexico Overactive Bladder Treatment, by Diagnosis Types USD Million (2015-2020)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Overactive Bladder Treatment: by Type(USD Million)
  • Table 141. Overactive Bladder Treatment Self-Care (Absorbent Pads, Scheduled Toileting, Double Voiding, Bladder Training) , by Region USD Million (2021-2026)
  • Table 142. Overactive Bladder Treatment Therapies (Biofeedback, Kegel Exercise) , by Region USD Million (2021-2026)
  • Table 143. Overactive Bladder Treatment Medications (Bladder Relaxant) , by Region USD Million (2021-2026)
  • Table 144. Overactive Bladder Treatment Specialists (Primary Care Provider, Geriatrician, Physiotherapist, Urologist, Obgyn Doctor) , by Region USD Million (2021-2026)
  • Table 145. Overactive Bladder Treatment: by Application(USD Million)
  • Table 146. Overactive Bladder Treatment Men , by Region USD Million (2021-2026)
  • Table 147. Overactive Bladder Treatment Women , by Region USD Million (2021-2026)
  • Table 148. Overactive Bladder Treatment Children , by Region USD Million (2021-2026)
  • Table 149. Overactive Bladder Treatment: by Surgery Type(USD Million)
  • Table 150. Overactive Bladder Treatment Sacral Nerve Stimulation , by Region USD Million (2021-2026)
  • Table 151. Overactive Bladder Treatment Urinary Diversion , by Region USD Million (2021-2026)
  • Table 152. Overactive Bladder Treatment Cystoplasty , by Region USD Million (2021-2026)
  • Table 153. Overactive Bladder Treatment Bladder Removal , by Region USD Million (2021-2026)
  • Table 154. Overactive Bladder Treatment: by Diagnosis Types(USD Million)
  • Table 155. Overactive Bladder Treatment Urine Sample , by Region USD Million (2021-2026)
  • Table 156. Overactive Bladder Treatment Physical Examination , by Region USD Million (2021-2026)
  • Table 157. Overactive Bladder Treatment Bladder Scan , by Region USD Million (2021-2026)
  • Table 158. Overactive Bladder Treatment Urodynamic Testing , by Region USD Million (2021-2026)
  • Table 159. Overactive Bladder Treatment Cystoscopy , by Region USD Million (2021-2026)
  • Table 160. South America Overactive Bladder Treatment, by Country USD Million (2021-2026)
  • Table 161. South America Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 162. South America Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 163. South America Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 164. South America Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 165. Brazil Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 166. Brazil Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 167. Brazil Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 168. Brazil Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 169. Argentina Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 170. Argentina Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 171. Argentina Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 172. Argentina Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 173. Rest of South America Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 174. Rest of South America Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 175. Rest of South America Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 176. Rest of South America Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 177. Asia Pacific Overactive Bladder Treatment, by Country USD Million (2021-2026)
  • Table 178. Asia Pacific Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 179. Asia Pacific Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 180. Asia Pacific Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 181. Asia Pacific Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 182. China Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 183. China Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 184. China Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 185. China Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 186. Japan Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 187. Japan Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 188. Japan Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 189. Japan Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 190. India Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 191. India Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 192. India Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 193. India Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 194. South Korea Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 195. South Korea Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 196. South Korea Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 197. South Korea Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 198. Taiwan Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 199. Taiwan Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 200. Taiwan Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 201. Taiwan Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 202. Australia Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 203. Australia Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 204. Australia Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 205. Australia Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 210. Europe Overactive Bladder Treatment, by Country USD Million (2021-2026)
  • Table 211. Europe Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 212. Europe Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 213. Europe Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 214. Europe Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 215. Germany Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 216. Germany Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 217. Germany Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 218. Germany Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 219. France Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 220. France Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 221. France Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 222. France Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 223. Italy Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 224. Italy Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 225. Italy Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 226. Italy Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 227. United Kingdom Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 228. United Kingdom Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 229. United Kingdom Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 230. United Kingdom Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 231. Netherlands Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 232. Netherlands Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 233. Netherlands Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 234. Netherlands Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 235. Rest of Europe Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 236. Rest of Europe Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 237. Rest of Europe Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 238. Rest of Europe Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 239. MEA Overactive Bladder Treatment, by Country USD Million (2021-2026)
  • Table 240. MEA Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 241. MEA Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 242. MEA Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 243. MEA Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 244. Middle East Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 245. Middle East Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 246. Middle East Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 247. Middle East Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 248. Africa Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 249. Africa Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 250. Africa Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 251. Africa Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 252. North America Overactive Bladder Treatment, by Country USD Million (2021-2026)
  • Table 253. North America Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 254. North America Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 255. North America Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 256. North America Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 257. United States Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 258. United States Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 259. United States Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 260. United States Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 261. Canada Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 262. Canada Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 263. Canada Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 264. Canada Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 265. Mexico Overactive Bladder Treatment, by Type USD Million (2021-2026)
  • Table 266. Mexico Overactive Bladder Treatment, by Application USD Million (2021-2026)
  • Table 267. Mexico Overactive Bladder Treatment, by Surgery Type USD Million (2021-2026)
  • Table 268. Mexico Overactive Bladder Treatment, by Diagnosis Types USD Million (2021-2026)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Overactive Bladder Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Overactive Bladder Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Overactive Bladder Treatment: by Surgery Type USD Million (2015-2020)
  • Figure 7. Global Overactive Bladder Treatment: by Diagnosis Types USD Million (2015-2020)
  • Figure 8. South America Overactive Bladder Treatment Share (%), by Country
  • Figure 9. Asia Pacific Overactive Bladder Treatment Share (%), by Country
  • Figure 10. Europe Overactive Bladder Treatment Share (%), by Country
  • Figure 11. MEA Overactive Bladder Treatment Share (%), by Country
  • Figure 12. North America Overactive Bladder Treatment Share (%), by Country
  • Figure 13. Global Overactive Bladder Treatment share by Players 2020 (%)
  • Figure 14. Global Overactive Bladder Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Overactive Bladder Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Allergan PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 18. Allergan PLC (Ireland) Revenue: by Geography 2020
  • Figure 19. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Astellas Pharma Inc. (Japan) Revenue: by Geography 2020
  • Figure 21. Cogentix Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Cogentix Medical Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Endo International PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Endo International PLC (Ireland) Revenue: by Geography 2020
  • Figure 25. Hisamitsu Pharmaceutical Co. Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 26. Hisamitsu Pharmaceutical Co. Inc. (Japan) Revenue: by Geography 2020
  • Figure 27. Medtronic PLC (Medtronic PLC) Revenue, Net Income and Gross profit
  • Figure 28. Medtronic PLC (Medtronic PLC) Revenue: by Geography 2020
  • Figure 29. Pfizer Inc. (Pfizer Inc.) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer Inc. (Pfizer Inc.) Revenue: by Geography 2020
  • Figure 31. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France) Revenue: by Geography 2020
  • Figure 33. Teva Pharmaceutical Industries Limited (Israel) Revenue, Net Income and Gross profit
  • Figure 34. Teva Pharmaceutical Industries Limited (Israel) Revenue: by Geography 2020
  • Figure 35. Mayo Clinic (United States) Revenue, Net Income and Gross profit
  • Figure 36. Mayo Clinic (United States) Revenue: by Geography 2020
  • Figure 37. Global Overactive Bladder Treatment: by Type USD Million (2021-2026)
  • Figure 38. Global Overactive Bladder Treatment: by Application USD Million (2021-2026)
  • Figure 39. Global Overactive Bladder Treatment: by Surgery Type USD Million (2021-2026)
  • Figure 40. Global Overactive Bladder Treatment: by Diagnosis Types USD Million (2021-2026)
  • Figure 41. South America Overactive Bladder Treatment Share (%), by Country
  • Figure 42. Asia Pacific Overactive Bladder Treatment Share (%), by Country
  • Figure 43. Europe Overactive Bladder Treatment Share (%), by Country
  • Figure 44. MEA Overactive Bladder Treatment Share (%), by Country
  • Figure 45. North America Overactive Bladder Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan PLC (Ireland)
  • Astellas Pharma Inc. (Japan)
  • Cogentix Medical Inc. (United States)
  • Endo International PLC (Ireland)
  • Hisamitsu Pharmaceutical Co. Inc. (Japan)
  • Medtronic PLC (Medtronic PLC)
  • Pfizer Inc. (Pfizer Inc.)
  • Sanofi (France)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Mayo Clinic (United States)
Additional players considered in the study are as follows:
Macleods Pharmaceuticals Ltd. (India) , Intas Pharmaceuticals Ltd. (India) , Apotex Inc. (Canada)
Select User Access Type

Key Highlights of Report


Sep 2021 246 Pages 50 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global and Regional Overactive Bladder Treatment Market Quantitative research analysis
Global and Regional Overactive Bladder Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Overactive Bladder Treatment Market are Allergan PLC (Ireland), Astellas Pharma Inc. (Japan), Cogentix Medical Inc. (United States), Endo International PLC (Ireland), Hisamitsu Pharmaceutical Co. Inc. (Japan), Medtronic PLC (Medtronic PLC), Pfizer Inc. (Pfizer Inc.), Sanofi (France), Teva Pharmaceutical Industries Limited (Israel) and Mayo Clinic (United States) etc.
Overactive bladder causes change or problems in urine to create overactive bladder diseases. There is strong growth potential in the United State region, where 33 million Americans affected by an overactive bladder. It could be a medical composite. Due to the increasing ration of this disease makes companies invest in this market, with advanced technologies.

Know More About Global and Regional Overactive Bladder Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Ankylosing Spondylitis Comprehensive Study by Application (Hospitals, Clinics, Ambulatory Surgical Centers), Route of Administration (Oral, Parenteral), Treatment Type (Nonsteroidal Anti-Inflammatory...
$ 3750
Infantile Spasms Therapeutics Comprehensive Study by Type (Monotherapy, Combination Therapy), Drug Form (Solid, Liquid), End Users (Infants, Children < 2 Years), Route of Administration (Oral, Parent...
$ 3500
Dry Eye Disease Comprehensive Study by Type (Artificial Tears, Anti-inflammatory Drugs, Punctal Plugs, Secretagogue), Application (Hospital Pharmacies, Independent Pharmacies & Drug Stores, Online Ph...
$ 3450
Hypercalcemia Treatment Comprehensive Study by Application (Mild Hypercalcemia, Moderate Hypercalcemia, Severe Hypercalcemia), Treatment (Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidro...
$ 3650
Postpartum Hemorrhage Comprehensive Study by Type (Early Postpartum Hemorrhage, Late Postpartum Hemorrhage), Application (Hospitals, Clinics, Other), Drugs (Oxytocin, Prostaglandins (Dinoprostone, Mi...
$ 3750
Cancer Therapeutics and Biotherapeutics Comprehensive Study by Type (Chemotherapy, Radiation Therapy, Hormone Therapy, Biotherapy), Application (Household, Hospital, Others), Therapy Type (Monoclonal...
$ 3800